SISB INVESTMENT ADVISERS (UK) LTD

Institutional investor · Portfolio as of Q2 2026

Top Holdings9 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

COUPANG INC

289.5M$5B65.6%$49.35-66.50%
22 qtrssince 2021-Q1
Unchanged
0

GRAB HOLDINGS LTD - CL A

401.8M$1.5B19.8%$7.08-48.62%
19 qtrssince 2021-Q4
Unchanged
0

RELAY THERAPEUTICS INC

27.9M$522.1M6.8%$39.98-51.33%
24 qtrssince 2020-Q3
Unchanged
0

COMPASS INC

21.5M$265.2M3.5%$13.50-15.70%
21 qtrssince 2021-Q2
Decreased
0

VIR BIOTECHNOLOGY INC

10.9M$111.6M1.5%$12.12-8.58%
27 qtrssince 2019-Q4
Unchanged
0

AURORA INNOVATION INC

14.3M$97.4M1.3%$11.26-48.85%
19 qtrssince 2021-Q4
Decreased
0

ENERGY VAULT HOLDINGS INC

15.5M$73.2M1.0%$9.89-62.59%
17 qtrssince 2022-Q2
Unchanged
0
YMMYMM
ADR

FULL TRUCK ALLIANCE CO LTD

5.3M$42.8M0.6%$12.11-27.18%
16 qtrssince 2022-Q3
Unchanged
0

GINKGO BIOWORKS HOLDINGS INC

610,729$6.1M0.1%$67.60-89.30%
15 qtrssince 2022-Q4
Unchanged
0
$7.7B
AUM
9
Positions
Q2 2026
Filing
1.0/5
HI score
Quarterly 13F Value Change
-4%Q1'25$11B+15%Q2'25$12.6B+5%Q3'25$13.3B-25%Q4'25$10B-23%Q1'26$7.7B-1%Q2'26$7.7B
Activity profile
$ moved · Q2'26
New0%Increased0%Decreased62%Exited38%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 4.6 years
<1Q0%1-4Q0%1-2Y11%2Y+89%

SB INVESTMENT ADVISERS (UK) LTD manages $7.7B across 9 positions as of Q2 2026. Top holdings: CPNG (65.6%), GRAB (19.8%), RLAY (6.8%). Fund DNA: Concentrated Value. HoldingsIntel Score: 1/5.0.

Q2 2026 Summary

Exited 1, trimmed 2. No standout high-conviction moves this quarter. Portfolio: $7.7B across 9 positions.

Top holdings by portfolio weight

Total AUM$8B
CPNG65.64%
GRAB19.77%
RLAY6.81%
COMP3.46%
VIR1.46%
AUR1.27%
NRGV0.95%
YMM0.56%
DNA0.08%
ROIV0.00%

Portfolio allocation by GICS sector

Sectors5
Consumer Cyclical65.64%
Technology21.60%
Healthcare8.35%
Real Estate3.46%
Utilities0.95%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Consumer Cyclical, Technology
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L4
Conviction37
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Top Losers

Checking access…

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used